A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Exclusion Criteria

• •Has received another new chemical entity
• •History of any disease or disorder which may put participant at risk in the study
• •Current or recurrent disease of clinical significance
• •Medical history of malignancies except for cervical carcinoma and non-melanoma skin cancer (NMSC)
• •Any clinically important illness, medical/procedure, or trauma
• •Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis result at screening
• •Any positive result on screening for serum hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HbcAb), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV)
• •History of latent or active tuberculosis (TB) or exposure to endemic areas
• •Evidence of active TB or untreated/inadequately/inappropriately treated for latent TB
• •Positive testing for Covid-19 prior to dosing, case of Covid-19 within 4 weeks, or long-term Covid-19-related sequelae
• •Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing or presence of fever
• •Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead electrocardiogram (ECG), and any clinically important abnormalities in the 12-lead ECG
• •Known or suspected history of alcohol or drug abuse or excessive intake of alcohol
• •History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity